Longer Term Follow Up of iFCR Shows Functional Cure for Individuals With Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how iFCR therapy increases the chance of functional cure for younger individuals with chronic lymphocytic leukemia.

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed how iFCR therapy increases the chance of functional cure for younger individuals with CLL.